Moberg Pharma: Record high after deal with Bayer, strong Q4

Moberg Pharma AB (publ)

12/02/2019 08:36

** Shares in Swedish pharma company  MBPH.ST  up 49 pct
after deal with Bayer, strong Q4 figures
    ** Co signs exclusive license agreement with Bayer for its
new onychomycosis treatment, MOB-015  urn:newsml:reuters.com:*:nWkr1gckxt
    ** The deal can bring up to EUR 50 mln in total milestone
payments 
    ** Co also divests its OTC business for $155 mln to focus
resources on the MOB-015 pipeline program 
    ** Posts Q4 revenue of SEK 97.1 mln, above SEK 90.0 mln
expected in Refinitiv IBES data  urn:newsml:reuters.com:*:nWkr9MxVKK
    ** Co cites strong US sales in qtr 
    

 ((marta.frackowiak@tr.com))